Peginterferon Alpha-2b Therapy in Chronic Hepatitis Patients With Normal ALT Level and Low Viremia

Inclusion Criteria: 1. willing to receive the treatment and sign informed consent; 2. 18-60 years old (including 18 and 60), both gender; 3. HBsAg positive for at least 6 months and \<1500IU/ml; 4. ALT≤1xULN and no elevated ALT has been detected in history; 5. HBV DNA detectable but\<2000 IU/ml; 6. HBeAg negative ; Exclusion Criteria: 1. For female participants: positive pregnancy test, presently breast-feeding, or unwillingness to use effective contraceptive measures for the duration of the study. For male participants: intent to procreate 3 months before or after the intervention or unwillingness to use effective measures of the contraception ; 2. neuropsychiatric diseases, such as depression, anxiety, mania, schizophrenia, or a family history of mental illness (especially with a history of depression or depression tendency); 3. co-infection of HCV, EBV, other hepatotropic viruses , non-hepatotropic viruses; 4. alcoholic hepatitis, drug-induced hepatitis, autoimmune liver disease; 5. Patients with moderate to severe steatohepatitis; 6. possibility of liver cirrhosis that cannot be excluded 7. hepatocellular carcinoma or AFP level\>30ng/ml; 8. Kidney diseases: acute and chronic nephritis, renal insufficiency, nephrotic syndrome, serum creatinine\> 1 x ULN at the time of screening; 9. at screening, the neutrophil count is less than 1.5×10\^9/L, and the platelet count is less than 90×10\^9/L; 10. Serum phosphorus level \<0.7 mmol/L; 11. Antinuclear antibody (ANA)\>1:100; 12. Autoimmune diseases, including thyroiditis, psoriasis and systemic lupus erythematosus; 13. Endocrine system diseases, including thyroid diseases and diabetes mellitus; 14. Uncontrolled blood pressure: SBP\>160 mmHg or DBP \>100 mmHg at the time of enrollment; 15. Evidence of cardiovascular disease, existing congestive cardiac failure on physical exam and/or acute coronary syndrome in the past 6 months; 16. Severe retinopathy or other serious eye diseases; 17. Organic disease or dysfunction; 18. plan to receive an organ transplant or have already undergone an organ transplant; 19. received standardized treatment with interferon or NA products before . 20. allergic to interferon or pharmaceutical excipients, or meet any of the contraindications in the experimental drug instructions; 21. Participated in other interventional trials within 3 months before the screening or other conditions deemed unsuitable by the investigator.